Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : The Trump Presidency -- Ignore unavailable to you. Want to Upgrade?

To: i-node who wrote (164617)	5/19/2020 6:23:13 AM
From: Lane3	1 Recommendation Recommended By bentway Read Replies (2) \| Respond to of 361397

Pretty sure this is done routinely. We absolutely do not routinely conduct trials that require both experimental and control group to be purposely exposed to something potentially damaging, even deadly. "Routine" trials are designed around sick people and a drug that could potentially render them unsick. The risk to the experimental participants is mostly disappointment, possible previously undetected side effects. The risk to the control group, negligible. A trial for a prophylactic for a deadly disease, OTOH, is not just the opposite of what we do routinely but a different paradigm. The participants in both groups are healthy. The object would be for the participants in the control group to experience more negative effects than the participants in the experimental group. Success would present as having caused greater harm to the control group than to the experimental group. So, how would you get volunteers for your trial and would the trial be ethical?